Search for: "DAIICHI SANKYO US HOLDINGS, INC"
Results 1 - 20
of 20
Sorted by Relevance
|
Sort by Date
13 Mar 2014, 2:07 pm
Daiichi Sankyo Inc., Case. [read post]
27 Jan 2014, 9:47 am
Indianapolis, Indiana - An Indiana patent attorney sued in the Southern District of Indiana on behalf of Eli Lilly and Company of Indianapolis, Indiana; Daiichi Sankyo Co., Ltd. of Tokyo, Japan ("Daiichi Sankyo"); Daiichi Sankyo, Inc. of Parsippany, New Jersey ("DSI"); and Ube Industries, Ltd. of Yamaguchi, Japan alleging that Par Pharmaceutical Companies, Inc. [read post]
17 Jul 2014, 10:58 am
., an Indiana patent attorney for Eli Lilly and Company of Indianapolis, Indiana; Daiichi Sankyo Co., Ltd of Tokyo, Japan; Daiichi Sankyo, Inc. of Parsippany, New Jersey; and Ube Industries, Ltd. of Yamaguchi, Japan sued in the Southern District of Indiana alleging that First Time US Generics LLC of Broomall, Pennsylvania infringed Effient® products, Patent Nos. 8,404,703 and 8,569,325 which have been issued by the U.S. [read post]
1 Dec 2009, 9:45 am
Ltd. and Daiichi Sankyo Inc. v. [read post]
24 Mar 2010, 4:45 am
Mylan (EPLAW) Colmetec (Olmesartan medoxomil, Hydrochlorothiazide) - France: Cour d'Appel of Paris dismisses appeal of Daiichi Sankyo lodged against decision of French Patent Office rejecting its French SPC: Daiichi Sankyo Company Limited v. [read post]
20 Jan 2016, 8:00 am
KFx Medical Corporation, No. 15-291 Daiichi Sankyo, Inc., et al. v. [read post]
3 Mar 2008, 9:27 pm
Daiichi Sankyo Co. v. [read post]
17 Apr 2009, 12:00 am
Eli Lilly invalid (Patent Baristas), (Law 360) (Patent Docs) Gleevec / Glivec (Imatinib) – Novartis alpha crystalline form patent invalidated at pre – grant opposition (PatentCircle) Levaquin (Levofloxacin) - Daiichi Sankyo Co. [read post]
1 Apr 2016, 8:22 am
Petitions for Writ of Certiorari Denied or Dismissed: Daiichi Sankyo Company, Ltd. v. [read post]
25 Oct 2015, 1:40 pm
Apotex and Daiichi Sankyo v. [read post]
18 May 2016, 8:19 am
MPHJ Technology Investments, LLC, No. 15-838 (Federal court jurisdiction in anti-troll consumer protection case) Daiichi Sankyo Company, Ltd. v. [read post]
3 Jun 2016, 6:40 am
MPHJ Technology Investments, LLC, No. 15-838 (Federal court jurisdiction in anti-troll consumer protection case) Daiichi Sankyo Company, Ltd. v. [read post]
28 Jun 2016, 6:41 am
Lexmark International, Inc., No. 15-1189 (unreasonable restraints on downstream uses) Post Grant Admin: MCM v. [read post]
11 Jul 2008, 4:30 am
: (Spicy IP), India: Ranbaxy-Daiichi deal – Opportunities for private equity companies in India: (Profitability through Simplicity), India: (KEI) Cracking open anti-competitive practices in the developing world: complaints, amendments and waivers: (Spicy IP), India: Is it one rule for Indian pharma companies and another one for those from abroad? [read post]
20 Jun 2008, 8:07 am
– Marks & Clerk Biotechnology Report 2008: (IP finance), Pfizer and Daiichi-Sankyo’s bidding for Ranbaxy: (IP ThinkTank), (IAM), (Managing Intellectual Property), (GenericsWeb), Cutting Edge Information study reveals 53% of pharma patents approach expiration before litigation strategies are implemented: (Peter Zura's 271 Patent Blog), Quanta and agricultural biotechnology: (Holman’s Biotech IP Blog), Breakthough by WHO will give poor… [read post]
18 Jul 2008, 8:34 am
: (GenericsWeb), Eularis analyses most effective generics defence strategies with new pharmaceutical industry report: (GenericsWeb), WIPO symposium to discuss life sciences multilateral environmental agreements: (Daily Dose of IP), Daiichi Sankyo and Ranbaxy confirm deal is binding and final, allay market rumour and speculation: (SmartBrief), Daiichi Ranbaxy takeover and the implications for the future of IP: (Spicy IP), Europe: Cancer Research Therapeutics’ RNAi… [read post]
8 Dec 2015, 2:22 pm
Daiichi Sankyo Inc., a global pharmaceutical company with its U.S. headquarters in New Jersey, paid $39 million to resolve allegations of false claims against the United States and state Medicaid programs. [read post]
13 Jun 2008, 3:40 am
: (Patent Docs), Generic drug developers will continue to take advantage of global demand for lower-priced drugs, with Teva poised to maintain lead position says Goldman Sachs analyst: (GenericsWeb), Daiichi Sankyo takeover of Ranbaxy: (Profitability through Simplicity), (Spicy IP), (GenericsWeb), Canada: Generics to penetrate 26% pharma market in Canada says RNCOS research: (GenericsWeb), Canada: Generic drug makers spreading misinformation about patent regulation amendments to… [read post]
22 Feb 2008, 6:00 pm
Signature Financial Group, Inc., and AT&T Corp. v. [read post]
6 Jun 2008, 6:49 am
Please join the discussion by adding your comments on any of these stories, and please do let us know if you think we’ve missed something important, or if there is a source you think should be monitored. [read post]
